1. Home
  2. CHRS

CHRS

Coherus BioSciences Inc.

Logo Coherus BioSciences Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-19-2024 4:00pm EST

$
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

Founded: 2010 Country:
United States
United States
Employees: N/A City: REDWOOD CITY
Market Cap: 248.0M IPO Year: 2014
Target Price: $8.75 AVG Volume (30 days): 3.2M
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.53 EPS Growth: N/A
52 Week Low/High: $1.43 - $8.65 Next Earning Date: 05-06-2024
Revenue: $257,244,000 Revenue Growth: 21.89%
Revenue Growth (this year): 3.85% Revenue Growth (next year): 36.42%

Share on Social Networks: